Jubilant Life gets USFDA nod for generic dementia tablets

Published On 2015-10-16 05:41 GMT   |   Update On 2022-12-05 11:15 GMT
NEW DELHI: Drug firm Jubilant Life Sciences has received final approval from the US health regulator for generic Memantine Hydrochloride tablets used for treatment of dementia in patients with Alzheimer's disease.

"The company has received abbreviated new drug application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Memantine Hydrochloride tablets USP, 5 mg and 10 mg," Jubilant Life Sciences said in a filing to BSE.

The product is a generic version of Forest Laboratories' Namenda tablets in the same strengths, it added.

The Memantine Hydrochloride tablets are used for treatment of moderate to severe dementia in patients with Alzheimer's disease, the company said.

"As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. These include 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe," it added.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News